Interview with Gao Tejia Cai Dajian: Launching 3 billion M&A funds to refine the investment in the medical industry
In recent years, mergers and acquisitions in the medical and health industry have quietly warmed up, and a new wave of investment has surged. Silently ploughing into the medical industry for many years, Gao Tejia naturally will not miss this opportunity. Not long ago, the agency announced the launch of a 3 billion-scale merger and acquisition fund, which was once again in the past two years with Dean Diagnostics and Boya Bio to establish three M&A funds.
Cai Dajian, founder and chairman of Gao Tejia Investment Group, the “old gunner†who has been involved in the Chinese capital market for more than 20 years, is now leading his team to a new round of M&A investment feast.
Gao Tejia Chairman Cai Dajian
Opened the road to specialization in 2012
As early as 2012, Gao Tejia innovatively put forward the concept of “investment in the theme industry†in the industry, which is also the most praised place in the industry today. In that year, after many IPO suspensions and the “People's PE†feast, Cai Dajian positioned Gao Tejia's development strategy on the theme of medical health investment and opened the road to specialization.
To mention this, Cai Dajian still can't conceal his pride: "The concept of focusing on the subject area is definitely the earliest institution that was explicitly proposed and implemented in China. It can be used for medical health by compressing other fields and even stopping it completely. Even now There are few such institutions in the country, and most organizations are still spreading pies."
Because of its strategic focus and industry accumulation over the years, Gao Tejia has a strong comprehensive competitiveness in the medical and health field, whether it is industrial judgment or the grasp of some core resources. Today, Gao Tejia invests in nearly 40 companies in the health care sector.
Medical mergers and acquisitions into "fragrant"
Gao Tejia has three main businesses: one is mergers and acquisitions and strategic equity investment, the second is ordinary PE, and the third is similar to early angels and VCs. “Current M&A and strategic equity investment are our coreâ€, Cai Dajian has repeatedly stressed.
At present, there are more than 200 medical listed companies in China, and the number will continue to grow rapidly in the future. The total market value is expected to exceed 6 trillion yuan. In the past ten years, the medical industry has not only outperformed the Chinese stock market, but also has a much higher growth rate than China's GDP growth, making it one of the most valuable investment industries.
In the industry's view, the integration of medicine, medical and other related fields has become a general trend. Cai Dajian said that the industry's investment mergers and acquisitions are now mostly in the "big and small" state, at an early stage. However, this momentum will extend to medium-sized enterprises and even large enterprises in the future. "Now it is big and small, and it may be a big eat in the future, a merger between China and China, and a merger among large enterprises."
In all of Gao Tejia's current investments, mergers and acquisitions occupy an absolute overwhelming position, and VC projects are relatively less. Specifically, 80% of the projects are currently mature, VC projects may rush to about 10% in the short term, and the future ratio may increase. "The medical health industry is still a segment of rapid growth. If there is a VC opportunity, we will also vote. In comparison, VC has more technical content than ordinary PE." Cai Dajian said.
Xos Syrup,Xylo-Oligosaccharides Food,Xos Prebiotic
Shandong Bailong Chuangyuan Bio-tech Co.,Ltd. Qingdao Branch , https://www.sdblcycn.com